Bexagliflozin
- Generic Name
- Bexagliflozin
- Brand Names
- Brenzavvy
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29ClO7
- CAS Number
- 1118567-05-7
- Unique Ingredient Identifier
- EY00JF42FV
- Background
Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge. SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is mainly expressed i...
- Indication
Bexagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Theracos
- Target Recruit Count
- 16
- Registration Number
- NCT03557658
- Locations
- 🇺🇸
Clinical Research Site 2, Saint Paul, Minnesota, United States
🇺🇸Clinical Research Site 1, Boston, Massachusetts, United States
An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
- First Posted Date
- 2018-05-02
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Theracos
- Target Recruit Count
- 673
- Registration Number
- NCT03514641
- Locations
- 🇺🇸
Clinical Research Site, Tacoma, Washington, United States
🇺🇸Clinical Research Site 2, Anderson, South Carolina, United States
Absolute Bioavailability Study With Bexagliflozin
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Theracos
- Registration Number
- NCT03417076
- Locations
- 🇺🇸
Clinical Research Site, Madison, Wisconsin, United States
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Theracos
- Target Recruit Count
- 48
- Registration Number
- NCT03296800
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
Bexagliflozin Drug/Drug Interaction Study With Digoxin
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Theracos
- Target Recruit Count
- 20
- Registration Number
- NCT03197324
- Locations
- 🇺🇸
Covance CRU, Daytona Beach, Florida, United States
Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection
- Conditions
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- Theracos
- Target Recruit Count
- 20
- Registration Number
- NCT03167411
- Locations
- 🇺🇸
Clinical Research Site, Evansville, Indiana, United States
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Theracos
- Target Recruit Count
- 386
- Registration Number
- NCT03115112
- Locations
- 🇵🇱
Clinical Research Site 7138, Lublin, Poland
🇵🇱Clinical Research Site 7137, Gdańsk, Poland
🇵🇱Clinical Research Site 7141, Kraków, Poland
Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
- Conditions
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Theracos
- Target Recruit Count
- 54
- Registration Number
- NCT02956044
- Locations
- 🇺🇸
Clinical Research Site, Evansville, Indiana, United States
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Theracos
- Target Recruit Count
- 312
- Registration Number
- NCT02836873
- Locations
- 🇯🇵
Research site, Sayama-shi, SAitama, Japan
🇪🇸Research Site, Valencia, Spain
Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Theracos
- Target Recruit Count
- 25
- Registration Number
- NCT02820298
- Locations
- 🇺🇸
Denver Clinical Research Unit, Lakewood, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.